CDRD is Canada’s national life sciences venture, powering the country’s life sciences industry by creating and growing companies of scale – while training the scientific and business talent needed to drive them to become leading global anchors for Canada.
We build collaborations with the very best partners from academia, industry, patient foundations, the investment community, and other Key Opinion Leaders to provide the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector — and ultimately into new therapies for patients.
Scroll down to find out how we do this...
Build New Companies of Scale
We work with investors, industry, and academia to proactively evaluate commercial opportunities, identify and advance promising technologies & platforms, and build compelling business cases and teams.
Scale-Up Existing Companies
We support Canadian SMEs by providing tailored access to world-class drug development infrastructure & commercialization/business experts to define and execute critical experiments that will maximize probability of future clinical success and attract capital.
Train Highly-Qualified Personnel
We offer three distinct & dedicated streams through The CDRD Academy: Executive Institute, Post-Graduate Institute & Undergraduate Institute.
June 3, 2019
With more than 25 years of experience in pharmaceutical R&D leadership and management, serving most recently as Site Head and Vice President of R&D at Vertex Pharmaceuticals Canada Inc., Dr. Bennani will be based in Montreal, and responsible for overseeing and advancing a portfolio of drug...Read MoreCDRD & NEOMED Institute Join Forces to Create a New...Read More
May 30, 2019
CDRD, Canada’s national life sciences venture, and NEOMED Institute, a leading not-for-profit R&D organization building an innovation ecosystem in Montréal, are pleased to announce that effective today, they are bringing their respective capabilities and resources together under a new co-founded pan-Canadian enterprise, adMare BioInnovations....Read MoreCDRD Academy Executive Institute Opens the Door to the Next...Read MoreadMare BioInnovations Appoints Dr. Youssef Bennani as...Read More
CDRD Academy Executive Institute Opens the Door to the Next Cohort of National Life Sciences LeadersApril 30, 2019
Building off a highly successful inaugural year, CDRD, Canada’s life sciences venture, is proud to open applications to its 2019-2020 Executive Institute – a 10-month, highly-focused executive development program custom-designed to grow and nurture the management talent that the Canadian life sciences sector needs to lead...Read More2019-2020 Launch of CDRD Academy’s Executive InstituteRead MoreCDRD & NEOMED Institute Join Forces to Create a New...Read More
April 23, 2019
Join us as we celebrate graduates from the first cohort, and kick-off the second session of our unique life sciences executive leadership program....Read MoreCDRD & TRIUMF Announce Collaboration to Revolutionize...Read MoreCDRD Academy Executive Institute Opens the Door to the Next...Read More
CDRD & TRIUMF Announce Collaboration to Revolutionize the Fight Against Cancer with Targeted Alpha TherapyApril 2, 2019
By combining TRIUMF’s expertise in manufacturing isotopes and radiolabelling conjugates with CDRD’s ability to identify and validate potential biological targets to develop therapeutic agents such as monoclonal antibodies, new “weaponized targeted therapies” can be created for the treatment of cancers with significant unmet medical need. In...Read MoreWhy Invest in CanadaRead More2019-2020 Launch of CDRD Academy’s Executive InstituteRead More
April 1, 2019
CDRD is a proud sponsor of the Healthkick Invest at part of Health Innovation Week hosted by MaRS Discovery District from April 2-3 in Toronto! Join our President and CEO Gordon McCauley who is part of a panel discussion entitled "Why Invest in Canada" with colleagues...Read MoreThe Renaissance of Radio Pharmaceuticals – A Commercial...Read MoreCDRD & TRIUMF Announce Collaboration to Revolutionize...Read More
March 28, 2019
CDRD is a proud sponsor of the TAT11 International Symposium on targeted alpha therapy hosted by Canadian Nuclear Laboratories. We are excited to be co-hosting a panel discussion “The Renaissance of Radio Pharmaceuticals – A Commercial Perspective”. Stay tuned for a big announcement in this field!...Read MoreCDRD Invests in Sitka Biopharma to Advance Bladder Cancer...Read MoreWhy Invest in CanadaRead More
February 11, 2019
This new investment will enable Sitka and its partner Cancer Research UK (CRUK) to accelerate critical development activities and rapidly enter clinical trials of STK-01, Sitka’s lead product for the treatment of bladder cancer....Read MoreCDRD Appoints Wendy Hurlburt & William Charnetski to...Read MoreThe Renaissance of Radio Pharmaceuticals – A Commercial...Read More
January 17, 2019
Vancouver, Canada: CDRD, Canada’s national life sciences venture, is pleased to announce the appointments of Ms. Wendy Hurlburt and Mr. William Charnetski as new Directors of the organization. Wendy Hurlburt, an executive with more than 20 years of global finance, operations and compliance experience in the...Read MoreCDRD Recognized as Top Employer for Science StudentsRead MoreCDRD Invests in Sitka Biopharma to Advance Bladder Cancer...Read More
December 10, 2018
CDRD has been selected for a Science Co-op Employer Recognition Award by the University of British Columbia (UBC). In addition, two of CDRD’s employees: David Shin, Data Integrity Manager and Eric Cruz, Associate Scientist in Biologics, have also been selected to receive Supervisor Awards....Read MoreCDRD Appoints Wendy Hurlburt & William Charnetski to...Read More
See what else is new
Sepset Biosciences is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier and more targeted treatment of...Read the article
Zucara is now moving forward with GLP toxicology, GMP manufacturing and other Investigational New Drug/Clinical Trial Application enabling activities to bring...Read the article
Outcomes with Impact
September 19, 2017
CDRD is committed to training the next generation of highly-qualified personnel to drive the development of innovations. Hear more about our unique Training Program and the opportunities it is creating from some of our young scientists…....Read MoreNovel therapies advancedRead More
August 24, 2017
CDRD has advanced 66 potential novel drug therapies towards the clinic. Many more are in production....Read MoreCommercial transactionsRead MoreTraining the Next GenerationRead More
August 11, 2017
CDRD has completed 14 commercial transactions including the merger of CDRD spin-off company, Kairos Therapeutics, with BC-based Zymeworks Inc. and creating one of Canada’s leading biotherapeutics companies....Read MoreSpin-off CompaniesRead MoreNovel therapies advancedRead More
August 11, 2017
CDRD has successfully created 7 spin-off companies including Kairos Therapeutics, Sitka Biopharma, Zucara Therapeutics, Precision Nanosystems, Immcure Therapeutics, Mesentech and Sepset Biopharma....Read MoreCommercial transactionsRead More
See what else is new
Working with CDRD
Academic discovery is the watering hole of innovation, but developing discoveries into new therapeutic products is a challenging process that requires complementary expertise, infrastructure and resources not typically available to an investigator. That's where CDRD comes in.
Whether a company is looking to accelerate development of their lead program or strengthen their pipeline by pulling a secondary program off the back-burner, CDRD provides solutions for whatever scientific and/or commercial roadblocks are impeding progress towards the next corporate value-creation point.